Pharmaceuticals

Milestone Pharmaceuticals

shopify

Conference Minutes

SHOP

OpenAI

DXYZ

PYPL

KLAR

PLUS

CART

MSFT

MSFL

MSFO

MSFD

MSFU

MSFX

MSFY

OPTI

MIST

<p>The following is the FY25Q3 earnings call minutes of <span class="security-tag" type="security-tag" counter_id="ST/US/SHOP" name="Shopify " trend="">$Shopify (SHOP.US)</span> organized by Dolphin Research. For earnings interpretation, please refer to &#34;Shopify: Is Imperfection Unacceptable, the Original Sin of High Valuation?&#34; 1. Review of Core Financial Information 1. Third-quarter stock-based compensation expense was $116 million, and capital expenditure was $6 million. Free cash flow for the third quarter reached $507 million, accounting for 18% of total revenue. The free cash flow profit margin for the first nine months of this year remained the same as the same period last year, at 16%; this quarter's transaction and loan losses accounted for approximately 5% of revenue...</p>

Shopify 

Paymentus

Destiny Tech100

Paypal

Klarna

Plus500 Ltd.

ePlus

Instacart（Maplebear）

Universal

General Motors

Microsoft

GraniteShares 2x Long MSFT Daily ETF

YieldMax MSFT Option Income Strategy ETF

Direxion Daily MSFT Bear 1x Shares

Direxion Daily MSFT Bull 2X Shares

T-Rex 2X Long Microsoft Daily Target ETF

Kurv Yield Premium Strategy Microsoft MSFT ETF

Optec International, Inc.

Shopify (Minutes): Optimistic about the enterprise market + AI development in e-commerce

TD Cowen Raises Milestone Pharmaceuticals' Stock Rating to Buy

Wells Fargo Analyst Maintains Buy Rating on Milestone Pharmaceuticals

Milestone Pharmaceuticals released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1235 (forecast USD -0.164)

Milestone Pharmaceuticals released FY2025 9 Months Earnings on November 12 (EST), with actual revenue of USD 0 and EPS of USD -0.632

Milestone Pharmaceuticals to Conduct Poster Presentation

Milestone Pharmaceuticals released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2 (forecast USD -0.1775)

Milestone Pharmaceuticals released FY2025 Semi-Annual Earnings on August 12 EST, with actual revenue of USD 0 and EPS of USD -0.5084

Milestone Pharmaceuticals Issuing Common Stock and Warrants to Raise Capital

Milestone Pharmaceuticals Inc issues ordinary shares to raise funds

Milestone Pharmaceuticals' Stock Down 24.2% Due to Equity Financing

Milestone Pharmaceuticals Inc Accepted CRL Response by FDA

Milestone Pharmaceuticals submits FDA response to Cardamyst CRL

HC Wainwright Reiterates Buy Rating on Milestone Pharmaceuticals

Milestone Pharmaceuticals released FY2025 Q1 earnings on May 14 EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3132 (forecast USD -0.185)

Milestone Pharmaceuticals Interacts with FDA on CARDAMYST

Milestone Pharmaceuticals Stock Drops 8%, TD Cowen Downgrades Rating to Hold

Milestone Pharmaceuticals Receives Complete Response Letter from FDA for CARDAMYST™ New Drug Application

Milestone Pharmaceuticals released FY2024 Q4 earnings on March 13 (EST), actual revenue 0 USD, actual EPS -0.1865 USD (forecast EPS -0.1525 USD)

Milestone Pharmaceuticals released FY2024 annual earnings on March 13 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.6673 USD (forecast -0.6225 USD)

Milestone Pharmaceuticals Inc Receives Notice of Allowance for New US Patent on ETRIPAMIL